Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ISRIB and Oxiracetam — mechanism, dosing, side effects, legal status, and pricing.
ISRIB is a non-peptide small-molecule eIF2B activator (bis-chlorophenoxyacetamide-cyclohexane class) that antagonizes the integrated stress response (ISR) by stabilizing the eIF2B guanine-nucleotide exchange factor complex. It is not an approved drug and has no completed human clinical trials or validated human safety or efficacy data. Chemically distinct eIF2B-activator analogs (DNL343, ABBV-CLS-7262) have reached human trials, but DNL343 missed primary endpoints in a Phase 2/3 ALS trial (January 2025). ISRIB is sold by reagent suppliers for research use only.
Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is NOT FDA-approved in the United States. The FDA has classified oxiracetam as a 'new drug' requiring approval and determined it does not qualify as a dietary supplement; in the US it is sold only as an unregulated gray-market research chemical.
ISRIB
Oxiracetam
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ISRIB
Oxiracetam
No pricing data yet.
Check Oxiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
ISRIB
1
COAs
99.8%
Avg purity
1
Labs
Oxiracetam
2
COAs
99.4%
Avg purity
2
Labs
No completed or published human clinical trials of ISRIB itself exist; it has no validated human pharmacokinetic, safety, or efficacy data. In mice, systemic ISRIB enhanced spatial and fear-associated long-term memory in healthy animals, reversed hippocampus-dependent spatial-learning and working-memory deficits weeks after traumatic brain injury, and reset elevated ISR activity in aged (18–24 month) mice, reversing age-related spatial-memory decline with a brief 3-day dosing course. In prion-disease transgenic mice, ISRIB partially restored protein synthesis and prevented neurodegeneration without the pancreatic exocrine toxicity seen with PERK-inhibitor approaches. In vitro and in a patient-derived xenograft mouse model, ISRIB combined with imatinib attenuated RAS/RAF/MAPK and STAT5 signaling and eliminated therapy-resistant chronic myeloid leukemia cells.
Key references
Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.
ISRIB and Oxiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs